Which has preferable earnings and valuation, IFRX or VOR?

Vor Biopharma has lower revenue, but higher earnings than InflaRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 10,954.50 -$51.63M -$0.58 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is IFRX or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Vor Biopharma N/A N/A N/A

Is IFRX or JBIO more profitable?

Jade Biosciences' return on equity of -49.11% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Jade Biosciences N/A -49.11% -45.62%

Which has stronger earnings and valuation, MGTX or IFRX?

InflaRx has lower revenue, but higher earnings than MeiraGTx. InflaRx is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 16.31 -$114.20M $0.71 19.46 InflaRx $30K 10,954.50 -$51.63M -$0.58 N/A

Is MGTX or IFRX more profitable?

MeiraGTx has a net margin of 19.87% compared to InflaRx's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets MeiraGTx 19.87% 283.85% 29.39% InflaRx N/A -53.56% -43.02%

Does the media refer more to MGTX or IFRX?

In the previous week, InflaRx had 5 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for InflaRx and 2 mentions for MeiraGTx. InflaRx's average media sentiment score of 0.95 beat MeiraGTx's score of 0.93 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, IMTX or IFRX?

InflaRx has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $54.60M 23.20 -$222.26M -$1.86 N/A InflaRx $30K 10,954.50 -$51.63M -$0.58 N/A

Is IMTX or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Immatics -495.71% -47.41% -39.45% InflaRx N/A -53.56% -43.02%

Does the media refer more to IMTX or IFRX?

In the previous week, Immatics had 5 more articles in the media than InflaRx. MarketBeat recorded 12 mentions for Immatics and 7 mentions for InflaRx. InflaRx's average media sentiment score of 0.95 beat Immatics' score of 0.92 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive InflaRx 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MLTX or IFRX more profitable?

InflaRx's return on equity of -53.56% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% InflaRx N/A -53.56% -43.02%

InflaRx (IFRX) Competitors

$2.23 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Compare

IFRX vs. VOR, JBIO, MGTX, IMTX, and MLTX

Should you buy InflaRx stock or one of its competitors? InflaRx's main competitors and comparable companies include Vor Biopharma (VOR), Jade Biosciences (JBIO), MeiraGTx (MGTX), Immatics (IMTX), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does InflaRx compare to Vor Biopharma?

InflaRx (NASDAQ:IFRX) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

InflaRx has a beta of 2.48, meaning that its stock price is 148% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

Vor Biopharma has lower revenue, but higher earnings than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	10,954.50	-$51.63M	-$0.58	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, InflaRx had 6 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for InflaRx and 1 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.89 beat InflaRx's score of 0.95 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Positive
Vor Biopharma	Very Positive

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vor Biopharma's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Vor Biopharma	N/A	N/A	N/A

InflaRx currently has a consensus target price of $7.33, indicating a potential upside of 228.85%. Vor Biopharma has a consensus target price of $43.38, indicating a potential upside of 91.50%. Given InflaRx's higher possible upside, equities analysts clearly believe InflaRx is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Vor Biopharma beats InflaRx on 7 of the 12 factors compared between the two stocks.

How does InflaRx compare to Jade Biosciences?

InflaRx (NASDAQ:IFRX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, InflaRx had 6 more articles in the media than Jade Biosciences. MarketBeat recorded 7 mentions for InflaRx and 1 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.87 beat InflaRx's score of 0.95 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Positive
Jade Biosciences	Very Positive

InflaRx has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

InflaRx currently has a consensus target price of $7.33, indicating a potential upside of 228.85%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 148.32%. Given InflaRx's higher probable upside, research analysts plainly believe InflaRx is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -49.11% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Jade Biosciences	N/A	-49.11%	-45.62%

InflaRx has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	10,954.50	-$51.63M	-$0.58	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Summary

InflaRx beats Jade Biosciences on 9 of the 15 factors compared between the two stocks.

How does InflaRx compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

MeiraGTx has a net margin of 19.87% compared to InflaRx's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
InflaRx	N/A	-53.56%	-43.02%

InflaRx has lower revenue, but higher earnings than MeiraGTx. InflaRx is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	16.31	-$114.20M	$0.71	19.46
InflaRx	$30K	10,954.50	-$51.63M	-$0.58	N/A

MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market.

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, InflaRx had 5 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for InflaRx and 2 mentions for MeiraGTx. InflaRx's average media sentiment score of 0.95 beat MeiraGTx's score of 0.93 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx currently has a consensus price target of $26.17, suggesting a potential upside of 89.34%. InflaRx has a consensus price target of $7.33, suggesting a potential upside of 228.85%. Given InflaRx's higher probable upside, analysts clearly believe InflaRx is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

MeiraGTx beats InflaRx on 10 of the 17 factors compared between the two stocks.

How does InflaRx compare to Immatics?

Immatics (NASDAQ:IMTX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

64.4% of Immatics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Immatics had 5 more articles in the media than InflaRx. MarketBeat recorded 12 mentions for Immatics and 7 mentions for InflaRx. InflaRx's average media sentiment score of 0.95 beat Immatics' score of 0.92 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
InflaRx	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.20	-$222.26M	-$1.86	N/A
InflaRx	$30K	10,954.50	-$51.63M	-$0.58	N/A

Immatics presently has a consensus target price of $20.60, indicating a potential upside of 117.99%. InflaRx has a consensus target price of $7.33, indicating a potential upside of 228.85%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Immatics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
InflaRx	N/A	-53.56%	-43.02%

Summary

InflaRx beats Immatics on 10 of the 16 factors compared between the two stocks.

How does InflaRx compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, suggesting a potential upside of 63.92%. InflaRx has a consensus target price of $7.33, suggesting a potential upside of 228.85%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

InflaRx has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
InflaRx	$30K	10,954.50	-$51.63M	-$0.58	N/A

In the previous week, InflaRx had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 7 mentions for InflaRx and 1 mentions for MoonLake Immunotherapeutics. InflaRx's average media sentiment score of 0.95 beat MoonLake Immunotherapeutics' score of 0.94 indicating that InflaRx is being referred to more favorably in the news media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Positive
InflaRx	Positive

InflaRx's return on equity of -53.56% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
InflaRx	N/A	-53.56%	-43.02%

MoonLake Immunotherapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.48, suggesting that its share price is 148% more volatile than the broader market.

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

InflaRx beats MoonLake Immunotherapeutics on 13 of the 15 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$328.64M	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.84	11.68	273.17	25.45
Price / Sales	10,954.50	1,408.83	638.19	104.21
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	3.43	16.92	11.08	6.36
Net Income	-$51.63M	-$22.74M	$3.48B	$349.79M
7 Day Performance	8.78%	-0.13%	0.38%	-0.40%
1 Month Performance	31.18%	11.45%	7.89%	4.24%
1 Year Performance	39.38%	55.66%	24.71%	15.13%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.0213 of 5 stars	$2.23 flat	$7.33 +228.8%	+39.4%	$328.64M	$30K	N/A	60	Gap Up
VOR Vor Biopharma	2.1685 of 5 stars	$22.63 -3.8%	$43.38 +91.7%	-42.5%	$1.34B	N/A	N/A	140	Positive News Gap Up
JBIO Jade Biosciences	2.3989 of 5 stars	$20.98 -1.5%	$51.75 +146.7%	+163.8%	$1.33B	N/A	N/A	20	Positive News
MGTX MeiraGTx	3.9476 of 5 stars	$13.69 -3.2%	$26.17 +91.1%	+89.3%	$1.31B	$81.39M	19.28	300	Positive News
IMTX Immatics	2.8291 of 5 stars	$9.70 +3.6%	$20.60 +112.4%	+85.7%	$1.30B	$54.60M	N/A	260	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. VOR, JBIO, MGTX, IMTX, and MLTX

How does InflaRx compare to Vor Biopharma?

Summary

How does InflaRx compare to Jade Biosciences?

Summary

How does InflaRx compare to MeiraGTx?

Summary

How does InflaRx compare to Immatics?

Summary

How does InflaRx compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. VOR, JBIO, MGTX, IMTX, and MLTX

How does InflaRx compare to Vor Biopharma?

Which has more volatility & risk, IFRX or VOR?

Which has preferable earnings and valuation, IFRX or VOR?

Does the media prefer IFRX or VOR?

Do institutionals & insiders have more ownership in IFRX or VOR?

Is IFRX or VOR more profitable?

Do analysts recommend IFRX or VOR?

Summary

How does InflaRx compare to Jade Biosciences?

Do insiders and institutionals have more ownership in IFRX or JBIO?

Does the media favor IFRX or JBIO?

Which has more volatility and risk, IFRX or JBIO?

Do analysts recommend IFRX or JBIO?

Is IFRX or JBIO more profitable?

Which has better earnings & valuation, IFRX or JBIO?

Summary

How does InflaRx compare to MeiraGTx?

Is MGTX or IFRX more profitable?

Which has stronger earnings and valuation, MGTX or IFRX?

Which has more volatility and risk, MGTX or IFRX?

Do insiders & institutionals believe in MGTX or IFRX?

Does the media refer more to MGTX or IFRX?

Do analysts rate MGTX or IFRX?

Summary

How does InflaRx compare to Immatics?

Do institutionals and insiders have more ownership in IMTX or IFRX?

Does the media refer more to IMTX or IFRX?

Which has higher valuation & earnings, IMTX or IFRX?

Do analysts prefer IMTX or IFRX?

Which has more volatility & risk, IMTX or IFRX?

Is IMTX or IFRX more profitable?

Summary

How does InflaRx compare to MoonLake Immunotherapeutics?

Do analysts rate MLTX or IFRX?

Which has better earnings and valuation, MLTX or IFRX?

Does the media favor MLTX or IFRX?

Is MLTX or IFRX more profitable?

Which has more risk and volatility, MLTX or IFRX?

Do institutionals & insiders believe in MLTX or IFRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools